The maintenance phase challenge What happens when you stop: Appetite returns (gradually over weeks) Need to rely on habits built during weight loss Risk of regaining weight if not careful Success factors: How long you maintained at goal weight while on peptides Habits built during weight loss phase Continued protein intake and training Realistic expectations (some people maintain perfectly, others regain some) Tapering off GLP-1s Don't quit cold turkey: Gradually reduce dose over 4-8 weeks Example: 2.4mg 1.7mg 1mg 0.5mg 0.25mg stop This allows appetite to return gradually Gives you time to adjust habits While tapering: Monitor weight weekly If starting to regain, slow taper Maintain protein intake religiously Keep training consistent Long-term maintenance options Option 1: Cruise dose Stay on low dose GLP-1 indefinitely (0.25-0.5mg weekly) Maintains some appetite suppression Prevents regain Safer long-term than high doses Option 2: Cycle on/off 3-4 months on, 1-2 months off Return to peptides if weight creeps up 5+ pounds Allows body breaks from medication Option 3: Switch to sustainable peptides Transition from GLP-1s to CJC-1295/Ipamorelin Maintains metabolic benefits Supports muscle and recovery No appetite suppression (must rely on habits) Learn how to structure long-term protocols in our peptide cycle planning guide
doi: 10.1016/j.rbmo.2020.01.026 222 PlacidiMDi EmidioGVirmaniADAlfonsoAArtiniPGDAlessandroAMet al
Whether you've experienced pain after Wegovy injections or just want to know what to expect, this article has you covered
Morley adds, Despite vast increases in the number of products and competitors expected to enter the GLP-1R market, sales attributed to the 14 companies other than Eli Lilly and Novo Nordisk are forecast to generate only $8.8 billion in 2030, 15 times less than the combined valuation of the two leading companies. Amgen, the company ranked third in terms of GLP-1R sales in 2030, is forecast to generate only $3 billion, driven entirely by the product maridebart cafraglutide, which is currently in Phase II for type 2 diabetes and obesity
Portions that used to feel normal can now seem too much, while foods that were once enjoyable might suddenly not taste good
